Do Branched-Chain Amino Acids Have a Role in the Treatment of Hepatic Encephalopathy?

  • L. S. Eriksson
  • J. Wahren


The last decade has witnessed a dramatic growth of interest in the administration of branched-chain amino acids as a possible therapy in patients with liver cirrhosis and hepatic encephalopathy. These patients show elevated levels of the aromatic amino acids (tyrosine, phenylalanine and tryptophan) as well as methionine, while the concentrations of the branched-chain amino acids (BCAA) leucine, isoleucine and valine are decreased.1,2,3 The aromatic amino acids are of particular interest since they serve as precursors for the physiological neurotransmitters norepinephrine, dopamine and serotonin. Moreover, they compete with the BCAA for transport across the blood-brain barrier via the same transport system, the L-system.4 As a result of the increased availability of aromatic amino acids, the reduced levels of BCAA and probably also an augmented permeability of the blood-brain barrier,5 the brain uptake of aromatic amino acids may increase. This in turn has been suggested to result in the formation of “false” neurotransmitters such as octopamine and phenylethanolamine.6 These amines are less biologically active than the physiological neurotransmitters and are thought to accumulate and displace the latter, thereby causing cerebral dysfunction.


Hepatic Encephalopathy Aromatic Amino Acid Branch Chain Amino Acid Brain Uptake Plasma Amino Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    F. L. Iber, H. Rosen, S. M. Levenson, and T. C. Chalmers, The plasma amino acids in patients with liver failure, J. Lab. Clin. Med. 50: 417 (1957).PubMedGoogle Scholar
  2. 2.
    V. Iob, W. W. Coon, and M. Sloan, Free amino acids in liver, plasma, and muscle of patients with cirrhosis of the liver, J. Surg. Res. 7: 41 (1967).PubMedCrossRefGoogle Scholar
  3. 3.
    J. E. Fischer, N. Yoshimura, A. Aguirre, J. H. James, M. G. Cummings, R. M. Abel, and F. Deindoerfer, Plasma amino acids in patients with hepatic encephalopathy. Effect of amino acid infusions, Am. J. Surg. 127: 40 (1974).PubMedCrossRefGoogle Scholar
  4. 4.
    D. L. Oxender and H. N. Christiansen, Distinct mediating systems for the transport of neutral amino acids by the Ehrlich cell, J. Biol. Chem. 238: 3686 (1963).PubMedGoogle Scholar
  5. 5.
    J. H. James, J. Escourrou, and J. E. Fischer, Blood-brain neutral amino acid transport activity is increased after portacaval anastomosis, Science 200: 1395 (1978).PubMedCrossRefGoogle Scholar
  6. 6.
    J. E. Fischer and R. J. Baldessarini, False neurotransmitters and hepatic failure, Lancet 2: 75 (1971).PubMedCrossRefGoogle Scholar
  7. 7.
    J. E. Fischer and R. J. Baldessarini, Pathogenesis and therapy of hepatic coma, in: “Progress in Liver Diseases,” Popper and Schaffner, eds., Grune & Stratton, New York (1976).Google Scholar
  8. 8.
    J. E. Fischer, H. M. Rosen, A. M. Ebeid, J. H. James, J. M. Keane,and P. B. Soeters, The effect of normalization of plasma amino acids on hepatic encephalopathy in man, Surgery 80: 77 (1976).PubMedGoogle Scholar
  9. 9.
    L. Hagenfeldt, S. Eriksson, and J. Wahren, Influence of leucine on arterial concentrations and regional exchange of amino acids in healthy subjects, Clin. Sci. 59: 173 (1980).PubMedGoogle Scholar
  10. 10.
    S. Eriksson, L. Hagenfeldt, and J. Wahren, Intravenous infusion of a-ketoisocaproate - influence on amino acid and nitrogen metabolism in patients with liver cirrhosis, Clin. Sci. 62: 285 (1981).Google Scholar
  11. 11.
    Y. Sato, S. Eriksson, L. Hagenfeldt, and J. Wahren, Influence of branched-chain amino acid infusion on arterial concentrations and brain exchange of amino acids in patients with hepatic cirrhosis, Clin. Physiol. 1: 151 (1981).CrossRefGoogle Scholar
  12. 12.
    K. Krnjevie, Chemical nature of synaptic transmission in vertebrates, Physiol. Rev. 54: 418 (1974).Google Scholar
  13. 13.
    J. H. James, V. Ziparo, B. Jeppsson, and J. E. Fischer, Hyperammonaemia, plasma amino acid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy, Lancet ii: 772 (1979).Google Scholar
  14. 14.
    J. Wahren, P. Denis, P. Desurmont, L. S. Eriksson, J.-M. Escoffier, A. P. Gauthier, L. Hagenfeldt, H. Michel, P. Opolon, J. C. Paris, and M. Veyrac, Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? Hepatology, submitted (1983).Google Scholar
  15. 15.
    E. Holm, J. P. Striebel, E. Meisinger, P. Haux, W. Langhans, and H. D. Becker, Aminosäurengemische zur parenteralen Ernährung bei Leberinsuffiziens, Infusionstherapie 5: 274 (1978).Google Scholar
  16. 16.
    T. C. F. Aguilar and J. L. M. Picouto, Nutriciòn parenteral en 29 enfermos afectos de encefalopatia hepàtica tratodos con F.080, Rev. Clin. Esp. 155: 355 (1979).Google Scholar
  17. 17.
    H. Freund, J. Dienstag, J. Lehrich, N. Yoshimura, R. R. Bradford, R. Rosen, S. Atamian, E. Slemmer, J. Holroyde, and J. E. Fischer, Infusion of branched-chain enriched amino acid solution in patients with hepatic encephalopathy, Ann. Surg. 196: 209 (1982).PubMedCrossRefGoogle Scholar
  18. 18.
    H. Freund, N. Yoshimura, and J. E. Fischer, Chronic hepatic encephalopathy. Long-term therapy with a branched-chain aminoacid-enriched elemental diet, JAMA 242: 347 (1979).PubMedCrossRefGoogle Scholar
  19. 19.
    L. S. Eriksson, A. Persson, and J. Wahren, Branched-chain amino acids in the treatment of chronic encephalopathy, Gut 23: 801 (1982).PubMedCrossRefGoogle Scholar
  20. 20.
    D. Horst, N. Grace, H. 0. Conn, E. Schiff, S. Schenker, A. Viteri, D. Law, and C. E. Atterbury, A double-blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) supplement in cirrhotic patients with chronic portal-systemic encephalopathy. Annual Meeting of the American Association for the Study of Liver Diseases, Abstract 288 (1981).Google Scholar
  21. 21.
    H. Michel, G. Pomier-Layrargues, 0. Duhamel, B. Lacombe, G. Cuilleret, and H. Bellet, Intravenous infusion of ordinary and modified amino acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Abstract, Gastroenterol. 79: 1038 (1980).Google Scholar
  22. 22.
    W. J. Millikan, J. M. Henderson, W. D. Warren, S. P. Riepe, M. H. Kutner, L. Wright, J. Ziffer, and R. B. Parks, Total parenteral nutrition with F080 in cirrhotics with subclinical encephalopathy, Ann. Surg.(1982) in press.Google Scholar
  23. 23.
    A. McGhee, J. M. Henderson, W. J. Millikan, J. C. Bleier, M. Kassouny, R. Vogel, and D. Rudman, Comparison of the effects of hepatic-aid and a casein modular diet on encephalopathy, plasma amino acids, and nitrogen balance in cirrhotic patients, Ann. Surg, in press (1982).Google Scholar
  24. 24.
    G. Cuilleret, G. Pomier-Layrargues, F. Pons, J. Cadilhac, and H. Michel, Changes in brain catecholainine levels in human cirrhotic hepatic encephalopathy, J. grit. Soc. Gastroent. 21: 565 (1980).Google Scholar
  25. 25.
    J. E. Fischer, Amino acids in hepatic coma, Dig. Dis. Sci 27: 97 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • L. S. Eriksson
    • 1
  • J. Wahren
    • 1
  1. 1.Departments of Medicine and Clinical PhysiologyHuddinge University HospitalStockholmSweden

Personalised recommendations